<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79061">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02077946</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-4161</org_study_id>
    <secondary_id>U1111-1151-9632</secondary_id>
    <nct_id>NCT02077946</nct_id>
  </id_info>
  <brief_title>A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden</brief_title>
  <official_title>A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this study is to investigate a retrospective
      database assessment of clinical effectiveness in type 2 diabetes patients treated with
      liraglutide from primary care centers in Sweden.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Percent (%) of patients achieving at least 1 %-point HbA1c (glycosylated haemoglobin) reduction</measure>
    <time_frame>Day 0, Day 180</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent (%) of patients with HbA1c (glycosylated haemoglobin) reduction  at least 1 %-point and weight reduction at least 3% (NICE clinical guidelines, liraglutide only)</measure>
    <time_frame>Day 0, Day 180</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c (NGSP standard, in %) change</measure>
    <time_frame>Day 0, Day 180</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight (in kilograms)</measure>
    <time_frame>Day 0, Day 180</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure (systolic, in mmHg)</measure>
    <time_frame>From baseline to 180 days of therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids (HDL, LDL and triglycerides, in mmol/L)</measure>
    <time_frame>Day 0, Day 180</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in creatinine</measure>
    <time_frame>Day 0, Day 180</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Liraglutide / Sitagliptin</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>No treatment given.</description>
    <arm_group_label>Liraglutide / Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>No treatment given.</description>
    <arm_group_label>Liraglutide / Sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Data will be analyzed for patients with type 2 diabetes treated with liraglutide or
        sitagliptin from January 2010 to December 2013, with a treatment length of 180 days.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients from EMR (electronic medical record) system in the primary care in Sweden

          -  Patients equal to or more than 18 years of age

          -  Starting treatment with liraglutide or sitagliptin from January 2010 to December 2013

          -  Minimum of 180 days of prior follow-up/history within the database before their index
             date

        Exclusion Criteria:

          -  Patients with cancer, end stage liver disease, end stage renal failure (non-diabetes
             related)

          -  Female patients with gestational diabetes during pregnancy

          -  Patients with previous GLP-1 (glucagon-like peptide-1) or DPP-IV (dipeptidyl
             peptidase-4 ) inhibitor use, i.e. patients should be incretin naïve
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Malmö</city>
        <zip>202 15</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>February 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Sitagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
